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Background:We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of
human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-speciﬁc
pancreatic autoantibodies and assessed their clinical relevance in the largest inﬂammatory bowel disease
(IBD) cohort tested to date.
Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis
(UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls.
Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and speciﬁcity was 98% (95, 99),
while the sensitivity and speciﬁcity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined
testing led to a sensitivity of 31% and a speciﬁcity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2
(IgA or IgG) showed a sensitivity of 75% (70, 80) and a speciﬁcity of 84% (79, 89). IgA anti-MZGP2 antibodies
were more prevalent in CrD patients with early disease onset (p = 0.011). Also, anti-MZGP2 positive patients34
35
36
37Emore frequently had extensive disease with ileal involvement. Patients with longer disease duration weremore likely to have IgG anti-MZGP2 antibodies.Conclusions:Our novel ELISA conﬁrms the high speciﬁcity of anti-MZGP2 antibodies for CrD and their association
with disease severity phenotypes.© 2014 Published by Elsevier B.V.R
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1. Introduction
The exactmechanisms responsible for the induction of Crohn's disease
(CrD) as well as ulcerative colitis (UC), the other form of inﬂammatory
bowel disease (IBD), remain poorly understood [1–4]. Both diseases are
characterised by antibody seropositivity against distinct antigens, which54
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agnostic and clinical signiﬁcan
x.doi.org/10.1016/j.cca.2014.1complement the endoscopic and histological examinations used for the
prompt diagnosis of patients with suspected IBD [5,6].
The most widely used antibody marker for CrD is anti-Saccharomyces
cerevisiae antibody (ASCA), while the serological marker for UC is sero-
positivity for anti-neutrophil cytoplasmic antibodies (ANCAs) showing
an atypical perinuclear (p-ANCA) pattern by indirect immunoﬂuores-
cence assay (IFA) [5,6]. While most other antibody markers failed to
meet demanding clinical needs, pancreatic autoantibody (PAB) has
emerged as potentially diagnostically and clinically meaningful marker
for IBD [7]. Antigen-speciﬁc PABs against exocrine pancreas are present
in 20–30% of the patients with CrD, but in less than 2–9% of the patients
with UC, and can be found in very few patients with non-IBD related con-
ditions [8,9]. The recent identiﬁcation of themajor zymogen glycoprotein
2 (MZGP2) as the primary autoantigen of PAB [10,11] has prompted the
development of ELISAs or IFA techniques to allow the proper detection
of anti-MZGP2 PABs in routine practice [12,13]. Rodent pancreatic tissue
or GP2-over-expressed cell-lines have been used as substrates to test for
GP2-speciﬁc PABs by IFA [13,14], but because IFA procedures are
labour-intensive, time-consuming, and require experienced operators,ce of Crohn's disease-speciﬁc anti-MZGP2 pancreatic antibodies by a
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laboratories prefer to use ELISA-based assays [10–12,14–21]. ELISA testing
for anti-MZGP2 antibodies has recently become available [12], but the
assay is not FDA-approved for in vitro diagnostic use in the USA. In addi-
tion, the performance characteristics of these test systems have only
been compared to those obtained by in-house assays used for research
protocols in a small number of European Institutions [7,11,12,15–19].
The aim of the present study was to test a new, robust and highly
sensitive and speciﬁc anti-MZGP2 antibody ELISAs developed for com-
mercial use. To assess this we have tested a well-deﬁned cohort of IBD
patients including 323 CrD and 294 UC patients regularly followed up
in a tertiary centre. Testing of this homogenous cohort of patients
could allow proper assessment of the diagnostic and clinical relevance
of anti-MZGP2 antibodies.
2. Patients and methods
2.1. Patients
Six hundred seventeen consecutive patients with a diagnosis of IBD
(CrD 323, female/male 176/147, age 40 ± 14.3, disease duration
14 years IQR [7,22]; UC 294, female/male 141/153, age 48.7 ± 15.7,
disease duration 14 years IQR [6,25]), under regular follow-up in a
tertiary centre (University College London Hospitals, United Kingdom)
were included in this study.
The IBD patient characteristics are presented in Supplementary
Table 1. The IBD diagnosis was based on current standard clinical, radio-
logical, endoscopic, and histological criteria (Lennard-Jones criteria)
[22]. Demographics and disease information including age at study,
age at diagnosis, disease duration, location/extent and behaviour were
extracted from a prospectively updated IBD electronic database. The
disease phenotypes were determined according to the Montreal classi-
ﬁcation [23].
Additionally, 112 patients with various diseases were studied as
pathological controls, including serum samples from patients with the
following diagnoses: celiac disease (n = 20); chronic pancreatitis
(n = 19); diabetes mellitus (n = 20); primary sclerosing cholangitis
(n = 21); primary biliary cirrhosis (n = 10); autoimmune hepatitis/
PSC overlap syndrome (n=6); chronic hepatitis B (n=8); and chronic
hepatitis C (n = 8). Finally, 103 randomly selected blood donors (age
17–60, sex female/male 64/39) were also studied as normal controls.
Investigators performing tests were blinded to the patients' exact diag-
noses. All sera had been stored at−20 °C before analysis. Assays were
developed and sera were tested between January and September 2013.
2.2. IgA and IgG ASCA testing by ELISA
Determination of IgA and IgG ASCAs was determined by an FDA-
cleared ELISA (QUANTA Lite® ASCA IgG and ASCA IgA, Inova Diagnos-
tics) following the manufacturer's protocol. A cut-off for positivity was
set at 25 U (arbitrary units), as recommended by the manufacturer.
2.3. IgG and IgA anti-MZGP2 antibody testing by ELISA
MZGP2 IgG and IgA antibodies were detected by novel ELISAs (Inova
Diagnostics, Research Use Only) utilizing human recombinant MZGP2,
isoform 4 antigen UniProtKB: P55259. Brieﬂy, 100 μL of pre-diluted
control and diluted patient sera (1:100) was added to separate wells
of MZGP2 antigen-coated polystyrene microwells and incubated for
30 min at room temperature. Unbound sample was then washed away
and peroxidase-conjugated goat anti-human IgG antibody or anti-
human IgA antibody was added to each well. After another incubation
and washing steps, the remaining enzyme activity was measured by
adding tetramethylbenzidine chromogenic substrate for 30 min. Stop
solution (H2SO4) was added to terminate the reaction and absorbance
read at 450/620 nm. Results, expressed in arbitrary units (U), werePlease cite this article as: Pavlidis P, et al, Diagnostic and clinical signiﬁcan
novel ELISA, Clin Chim Acta (2014), http://dx.doi.org/10.1016/j.cca.2014.1calculated in reference to a kit-provided calibrator. Serum samples
showing ≥25 U were interpreted as positive.2.4. ANCA testing by IFA
ANCAs for IgG antibodies were evaluated by IFA using commercially
available human neutrophil slides (Nova Lite™, Inova Diagnostics).
Brieﬂy, samples were diluted at 1:20 and tested in accordance with
the manufacturer's instructions on ethanol- and formalin-ﬁxed human
neutrophil substrate slides. Results were reported as p-ANCA if a
perinuclear pattern was observed on ethanol and granular cytoplas-
mic on formalin slides, c-ANCA if both ethanol and formalin slides
resulted in a cytoplasmic pattern, and “atypical” p-ANCA if the pattern
was perinuclear on ethanol and negative on the formalin-ﬁxed slide.O
O2.5. Pancreatic antibodies (PAB) by IFA
PABs were detected by IFA on monkey pancreas tissue (Nova Lite™,
Inova Diagnostics) using sera at a 1:20 dilution and primate-absorbed
goat anti-human FITC conjugate.E
D
 P
R
2.6. Statistical methods
Variables were tested for normality with the Kolmogorov–Smirnov
test. Age is presented as mean and standard deviation (SD). Non-
parametric continuous variables including ASCAs and anti-MZGP2 titres
are given as median and interquartile range (IQR). The report of the
atypical ANCA is qualitative (positive or negative) based on immunoﬂu-
orescence review by one of the authors (DPB). Precision and reproduc-
ibility (intra- and inter-assay) of assays were evaluated according to
Clinical and Laboratory Standards Institute (CLSI) guideline EP5-A2. A
minimum of ﬁve samples including one high, one low, and 1 near deci-
sion point were run in duplicate in 2 runs/day for 20 days. We estimate
inter- and intra-assay reproducibility at less than 7 and 5% respectively.
The cut-off for anti-MZGP2 IgA and IgG assays was calculated by
plotting a receiver operator characteristic (ROC) curve by using the
test results of the patients with CrD versus controls (UC, healthy, other
pathological controls). The area under the curve (AUC) values is follow-
ed by a 95% conﬁdence interval (CI). The diagnostic value of ASCA, anti-
MZGP2 and atypical ANCA for the IBD population was assessed by cross
tabulation and calculation of sensitivity, speciﬁcity, and positive and
negative predictive values, all presented as percentages followed by
95% CI. The clinical signiﬁcance of the different antibodies was studied
with chi-square tests for every clinical variable (2 × 2 tables) and the
results are presented as odds ratios with 95% CI and p values. Associa-
tions between variables foundonunivariate analysis to have statistically
signiﬁcant (p b 0.05) high prevalence in patients testing positive for
individual autoantibodies or autoantibody combinations were further
tested by loglinear regression. Comparisons in titre medians between
different diseases or disease subgroups were performed using the
non-parametric Mann–Whitney or Kruskal–Wallis tests. Comparisons
of parametric variables (i.e. age) were performed using the unpaired t-
test. Cross tabulation and loglinear analysis were performed using
SPSS (SPSS Inc., Chicago, Illinois, USA) software. Prism software (by
GraphPad Software Inc., La Jolla, California, USA) was used for ROC
curve plotting, antibody titre comparisons and ﬁgures.2.7. Ethical considerations
The study was conducted in accordance with the Helsinki declara-
tion and approved by the local ethics committees. Written informed
consent was obtained from each individual.ce of Crohn's disease-speciﬁc anti-MZGP2 pancreatic antibodies by a
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Fig. 2. IgA (a) and IgG (b) anti-MZGP2 antibody reactivities in 323 patients with Crohn's
disease (CrD), 294with ulcerative colitis (UC) patients and in pathological controls includ-
ing patients with coeliac disease (n = 20); chronic pancreatitis (n = 19); diabetes
mellitus, DM (n = 20); primary biliary cirrhosis, PBC (n = 10); primary sclerosing
cholangitis, PSC ( Q1n = 21); autoimmune hepatitis (AIH)/PSC overlap syndrome (n = 6);
chronic viral hepatitis (viral hep) B (n= 8); and chronic viral hepatitis C (n= 8). Normal
controls consisted of 103 randomly selected blood donors.
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3. Results
3.1. Diagnostic accuracy of serological markers
Venn diagrams depicting numbers of CrD showing individual reactiv-
ities are shown in Fig. 1. Supplementary Fig. 1 shows individual responses
in patientswith UC. Scatter plots of anti-MZGP2 antibody reactivities (IgA
or IgG) in patients with CrD, UC, pathological, and normal controls are
shown in Figs. 2 & 3. The ROC curves for anti-MZGP2 IgA and IgG assays
(CrD vs controls) are also presented as inserts in Figs. 2 & 3. The calculated
AUCwas 0.56, 95%CI (0.56, 0.64) for IgA anti-MZGP2 [CrD vsnon-CrD (UC
and controls)] and 0.62, 95% CI (0.58, 0.67) for IgG anti-MZGP2. The sen-
sitivity, speciﬁcity and likelihood ratio for different cut-offs of anti-MZGP2
are presented in Table 1 (for CrD vs non-CrD cohorts, including UC, path-
ological and normal controls) and in Supplementary Table 2 (for CrD vs
UC), respectively.
The sensitivity of IgA anti-MZGP2 for CrD in the IBD population was
15% (11, 19) and the speciﬁcitywas 98% (95, 99), while the sensitivity of
IgG anti-MZGP2 for CrD was 27% (22, 32) and the speciﬁcity was 97%
(94–98) using the manufacturer's cut-off set at 25 U. In comparison,
the sensitivity of IgA and IgG ASCAs for CrD was 47% (41, 52) and 66%
(61, 71), respectively, while the speciﬁcity was 95% (92, 97) and 90%
(86, 93), respectively for CrD vs UC. The combination of positive IgA and
IgG ASCA testing increased the sensitivity to 71% (66, 76), but reduced
the speciﬁcity to 87% (83, 91). Positivity for either ASCA (IgA or IgG) or
anti-MZGP2 (IgAor IgG) showed a sensitivity of 75% (70, 80) and speciﬁc-
ity of 84% (79, 89).
The presence of any one of the autoantibodies (ASCA IgA, ASCA IgG,
MZGP2 IgA, MZGP2 IgG) yielded the highest sensitivity at 75% (70, 80),
but reduced speciﬁcity to 84% (79, 89). In contrast, while only 7% sensi-
tive the presence of all four autoantibodies (ASCA IgA, ASCA IgG,MZGP2
IgA, MZGP2 IgG) in 23 individuals (Table 2 and Fig. 1) was 100% speciﬁc
for CrD, being negative in all 294 patients with ulcerative colitis. Dual
positivity for MZGP2 IgA and IgG showed 99% speciﬁcity (11% sensitiv-
ity), followed by dual positivity for ASCA IgA and IgG at 98% speciﬁcity
and 42% sensitivity and single IgA MZGP2 positivity with a speciﬁcity
of 98% and a sensitivity of 15%.
The sensitivity of IgG atypical p-ANCA testing for UC in the IBD popu-
lation was 36% (31, 42) and the speciﬁcity was 91% (87, 94). Sensitivity,
speciﬁcity, and negative, and positive predictive values are presented for
all autoantibodies and their combinations in Table 2.U
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Fig. 1. Venn diagrams of individual IgA or IgG anti-Saccharomyces cerevisiae antibody
(ASCA) and anti-major zymogen granule membrane glycoprotein 2 (MZGP2) serum anti-
body reactivity of patients with Crohn's disease (CrD).
Please cite this article as: Pavlidis P, et al, Diagnostic and clinical signiﬁcan
novel ELISA, Clin Chim Acta (2014), http://dx.doi.org/10.1016/j.cca.2014.1E
DAs expected, ASCA and anti-MZGP2 antibody titres were higher inCrD compared to UC; the difference of the median titres for all antibody
reactivities between CrD and UC was statistically signiﬁcant (Mann–
Whitney, anti-MZGP2 IgA p = 0.0045, anti-MZGP2 IgG p b 0.0001,
ASCA IgA p b 0.0001 and ASCA IgG p b 0.0001). Supplementary Fig. 2
shows ASCA levels in IgA or IgG anti-MZGP2 antibody positive and neg-
ative patients with CrD.
3.2. Clinical signiﬁcance of antibody
Table 3 presents the associations between the autoantibodies and
different disease characteristics. IgA anti-MZGP2 antibodies were
more prevalent in patients with early disease onset (A1 b 16 years,Fig. 3. Q2
ce of Crohn's disease-speciﬁc anti-MZGP2 pancreatic antibodies by a
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t1:1 Table 1
t1:2 Diagnostic accuracy of anti-MZGP2 antibodies (IgA, IgG) for different cut-offs in Crohn's disease vs pathological (including ulcerative colitis) and normal controls. Results are presented as
t1:3 sensitivity (% and 95% conﬁdence interval values), speciﬁcity, (% and 95% conﬁdence interval values) and likelihood ratios.
t1:4 IgA anti-MZGP2 cut-off Sensitivity (%) 95% CI Speciﬁcity (%) 95% CI Likelihood ratio
t1:5 N10 31.27 26.25% to 36.63% 88.61 85.52% to 91.23% 2.74
t1:6 N15 23.84 19.30% to 28.87% 93.71 91.24% to 95.66% 3.79
t1:7 N20 17.96 13.93% to 22.59% 95.87 93.76% to 97.43% 4.35
t1:8 N25 14.55 10.89% to 18.88% 97.45 95.67% to 98.63% 5.70
t1:9 N30 12.07 8.729% to 16.13% 98.62 97.19% to 99.45% 8.78
t1:10 N40 10.22 7.138% to 14.05% 99.02 97.72% to 99.68% 10.40
t1:11 N10 39.94 34.56% to 45.51% 89.98 87.04% to 92.45% 3.99
t1:12 N15 34.67 29.49% to 40.14% 93.71 91.24% to 95.66% 5.52
t1:13 N20 30.34 25.37% to 35.67% 95.28 93.07% to 96.96% 6.43
t1:14 N25 26.63 21.88% to 31.80% 96.66 94.71% to 98.04% 7.97
t1:15 N30 25.08 20.44% to 30.17% 97.64 95.92% to 98.78% 10.64
t1:16 N40 22.29 17.87% to 27.23% 98.62 97.19% to 99.45% 16.21
t2:1
t2:2
t2:3
t2:4
t2:5
t2:6
t2:7
t2:8
t2:9
t2:10
t2:11
t2:12
t2:13
t2:14
t2:15
t2:16
t2:17
t2:18
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OR: 2.3 [1.2, 4.4], p = 0.011). Patients positive for IgG ASCA were
younger when compared to negative CrDs (mean age 22.92 ± 0.62
vs 28.02 ± 1.44, unpaired t test, p = 0.0002) and were less likely
to have late disease onset (A3) (p = 0.003 for IgG and p = 0.026
for IgA). Patients with A3 disease onset had lower titres for IgA or
IgG ASCA (median IgA ASCA titre for A1: 23.6, A2: 23.4, A3: 9, p =
0.002, median IgG ASCA titre for A1: 42, A2: 45.5, A3: 16.8, p =
0.001). Also, IgA anti-MZGP2 titres were higher in younger patients
(median IgA anti-MZGP2 titre for A1: 7.4, A2: 4.3, A3: 3.8, p = 0.04).
Patients positive for IgG anti-MZGP2 or (IgA or IgG) ASCAweremore
likely to have extensive CrD with ileal involvement (OR: 2.3, 1.7, 1.9,
respectively). The presence of both (IgA or IgG) anti-MZGP2 and (IgA
or IgG) ASCA increased the OR for extensive disease (L3) to 2.8 (1.5,
5.2). Patients with localised colonic disease were less likely to be posi-
tive for these antibodies; IgA ASCA, IgG ASCA and IgG anti-MZGP2 titres
were also lower in these patients and higher in patients with extensive
disease (median IgA ASCA titre for L1: 24.05, L2: 12.2, L3: 26.6, L4: 15.1,
p=0.02;median IgGASCA titre for L1: 46.95, L2: 16.8, L3: 49.1, L4: 54.5,
p = 0.001; median IgG anti-MZGP2 titres for L1: 4.55, L2: 3.7, L3: 7.4
0.156, L4: 3.7, p = 0.046; Supplementary Fig. 3).
Stricturing disease (B2) was more likely in patients tested positive
for IgG ASCA (OR: 2.3 [1.3, 4]), while the presence of both (IgA or IgG)
anti-MZGP2 and (IgA or IgG) ASCA increased the OR for B2 to 3.1 (1.5,
6.3). Antibody titres were also higher in B2 in comparison to B1, B3
(median ASCA IgA titre for B1: 17.3, B2: 29.1, B3: 25.35, p= 0.007, medi-
an IgGASCA titre for B1: 35.2, B2: 53.7, B3: 45.2, p=0.033). IgAASCA, IgG
ASCAor (IgA, IgG) anti-MZGP2was less prevalent in patientswith inﬂam-
matory behaviour (B1).
Patients with longer disease duration were more likely to have IgG
anti-MZGP2 (difference in medians: 2 years), or IgA ASCA antibodies
(difference in medians: 5.5 years).U
N
C
Table 2
Summary of sensitivity (% and conﬁdence interval values), speciﬁcity of individual antibody re
CrD (n = 323)
(positive, n)
IgA anti-MZGP2 pos 48
IgG anti-MZGP2 pos 87
IgA and/or IgG anti-MZGP2 pos 99
IgA and IgG anti-MZGP2 pos 36
IgA ASCA pos 151
IgG ASCA pos 213
IgA and/or IgG ASCA pos 230
IgA and IgG ASCA pos 134
(IgA or IgG) ASCA and/or (IgA or IgG) anti-MZGP2 pos 242
IgA and IgG ASCA pos and IgA and/or IgG anti-MZGP2 pos 171
IgA and IgG ASCA pos and IgA and IgG anti-MZGP2 pos 23
Atypical p-ANCA 30
IgA or IgG ASCA pos and atypical pANCA neg 214 (66%)
IgA or IgG MZGP2 pos and atypical pANCA neg 87
ANCA, anti-neutrophil cytoplasmic antibody; ASCA, anti-Saccharomyces cerevisiae antibody.
Please cite this article as: Pavlidis P, et al, Diagnostic and clinical signiﬁcan
novel ELISA, Clin Chim Acta (2014), http://dx.doi.org/10.1016/j.cca.2014.1E
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Atypical p-ANCAs were not associated with sex, age of onset,
disease duration, disease extent or the requirement for colectomy
and stoma formation in UC patients. UC patients positive for atyp-
ical p-ANCA though, were older on disease onset (mean age: 32.35
vs 25.67, p = 0.02) and had longer disease duration (median dura-
tion 16.5 vs 12, p = 0.03) when compared to positive patients
with CrD.
Of the 13 ulcerative colitis patients positive for MZGP2 IgG and/or
IgA, 2 were also positive for both ASCA IgG, ASCA IgA, and both IgG
and IgA pancreatic antibodies by IFA. Four other patients showed mod-
erate to strong PAB (IgG and/or IgA) by IFA. Of the 5 normal donors
found positive for MZGP2 IgG, 1 was ASCA IgG and IgA positive with
1–2+ IgA PAB, and 3 others showed 1–2+ IgA PAB and nonspeciﬁc
IgG PAB. The one very strong positive chronic pancreatitis patient
had no clinical features identiﬁed which distinguished them from the
other chronic pancreatitis patients.
4. Discussion
In the present study, we report on theﬁrst use of two recently devel-
oped, robust, highly speciﬁc ELISAs for the detection of IgA and IgG anti-
MZGP2 PABs, respectively. We have detected anti-MZGP2 antibodies in
31% of patients with CrD and just 4% of UC patients. Amongst the reac-
tive CrD patients, 27% and 15% showed IgG or IgA anti-MZGP2 reactivity,
while reactivity to both isotypes was concurrently present in 11% of the
CrD patients and only 1% of patients with UC.
Cumulatively, the new ELISAs demonstrate enhanced sensitivity and
superior speciﬁcity for CrD within IBD compared to those reported by
previous studies [7]. A recent study tested 3 cohorts – two from
Germany and one from our centre – and reported an overall (IgA or
IgG) anti-MZGP2 sensitivity and speciﬁcity of 30.2% and 91%,activities in 323 Crohn's disease (CrD) and 294 ulcerative colitis (UC) patients.
UC (n = 294)
(positive, n)
Sens % Sens CI% Spec % Spec CI%
7 15 11, 19 98 95, 99
10 27 22, 32 97 94, 98
13 31 25, 36 96 93, 98
4 11 8, 15 99 97, 99
14 47 41, 52 95 92, 97
29 66 61, 71 90 86, 93
37 71 66, 76 87 83, 91
6 42 36, 47 98 96, 99
47 75 70, 80 84 79, 88
0 53 47, 59 100 98, 100
0 7 5, 11 100 99, 100
106 36 31, 42 91 87, 94
22 (8%) 94 86, 98 80 64, 91
10 27 22, 32 97 94, 98
ce of Crohn's disease-speciﬁc anti-MZGP2 pancreatic antibodies by a
2.010
TF
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
t3:1Q3 Table 3
t3:2 Clinical relevanceof antibody reactivities inpatientswithCrohn's disease; rows corresponding to L1, L4, B3 andA2were omittedbecause statistically signiﬁcant differences for a givenparameter
t3:3 were not obtained; positive associations are indicated in bold and negative associations in italic (p values, odds ratio and range); A (age), L (location), and B (behaviour) according toMontreal
t3:4 classiﬁcation; L1, ileal; L2, colonic; L3, ileocolonic, and L4, upper disease modiﬁer; B1, non-stricturing/non-penetrating; B2, stricturing; B3, penetrating behaviour.
t3:5 p OR 95%
t3:6 CI
IgA
anti-MZGP2
IgG
anti-MZGP2
IgA or IgG
anti-MZGP2
IgA ASCA IgG ASCA IgA or IgG ASCA (IgA or IgG) ASCA or
(IgA or IgG) anti-MZGP2
(IgA or IgG) ASCA &
(IgA or IgG) anti-MZGP2
p-ANCA
t3:7 L2 0.002 0.007 0.0008 b0.0001 b0.0001 b0.0001 0.002
t3:8 L3 0.007
2.3 (1.2, 4.2)
0.013
2 (1.2, 3.6)
0.03
1.7 (1.1, 2.8)
0.003
1.9 (1.2, 3.2)
0.012
1.9 (1.2, 3.2)
0.001
2.8 (1.5, 5.2)
t3:9 B1 0.033 0.021 0.002 0.005 0.038
2.3 (1.1, 5.3)
t3:10 B2 0.006
2.3 (1.3, 4)
0.005
2.4 (1.3, 4.6)
0.001
3.1 (1.5, 6.3)
t3:11 A1 0.011
2.3 (1.2, 4.4)
0.043
1.8 (1.0, 3.1)
t3:12 A3 0.003 0.026 0.015
t3:13 Duration 0.018 0.026 b0.0001 0.019 0.008 0.034
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respectively [12]. Additional testing on a Belgium cohort using the GA
ELISA has showed anti-MZGP2 antibodies in 21% of CrD patients and 9%
of UC patients [16]. Interestingly, other studies reported GA ELISA anti-
MZGP2 antibody reactivity in up to 22% of patients with UC [7,11,12,
15–19]. The low speciﬁcity reported in the past for this assay raised signif-
icant concerns for the diagnostic utility of this test and its incorporation
into routine testing of individuals assessed for IBD. The lower sensitivity
and speciﬁcity in the Belgian cohorts [16] has been attributed to differ-
ences in the geographic origin of the patients and/or the selection criteria
for inclusion in the studies [20]. Methodological issueswere not raised, as
both studies have used the GA ELISA kit and were performed by exceed-
ingly qualiﬁed research laboratories.
Themajority of studies have agreed upon the fact thatmost IgA anti-
MZGP2 antibody positive CrD patients have concurrent IgG antibodies
against the same antigen [7,12,16,21]. In the present study, we also
noted that IgA anti-MZGP2 antibody positivity marginally increases
the over-all sensitivity of the test, as 3.7% (12/323, Fig. 1) of the CrD
patients had only IgA anti-MZGP2 antibodies. This ﬁnding points
towards the inadequate diagnostic utility of the IgA antibodies, but does
not exclude their clinical relevance, as positivity for IgA anti-MZGP2
reveals several clinical associations (see Table 3).
At a ﬁrst glance, ASCAs (IgA or IgG) remain the most sensitive
antibody tests for CrD with a sensitivity of 71% compared to 31% for
anti-MZGP2 (IgA or IgG) [5]. However, ASCA testing shows the lowest
speciﬁcity for CrD in IBD (87%),while that of anti-MZGP2 ismuchhigher
(96%). This difference in the overall speciﬁcity can be clinically signiﬁ-
cant. The sensitivity of anti-MZGP2 for CrD in IBD could be higher if
the cut-off was decreased, resulting though to lower speciﬁcity. For
example, if a 94% speciﬁcity was targeted, the cut-off could be lowered
to 15 U for both IgA and IgG anti-MZGP2, and the resulting sensitivity of
anti-MZGP2 for CrD could reach as much as 24% for IgA and 35% for IgG
anti-MZGP2 (Table 1). Studies directly investigating the performance of
the two assays in well-deﬁned IBD serum samples, pre-characterised as
‘equivocal’, low, or moderate level seropositive sera from IBD patients
and controls are needed to clarify this issue. The relatively low speciﬁc-
ity of ASCA for CrD in IBD is a well-described feature, and is one of the
greatest limitations of this test. Nevertheless, simultaneous detection
of anti-MZGP2 and ASCA (of any isotype) is practically absent in
patients with UC, hence combination of both assays could be used to
help “rule out” UC. In other words, if a patient with a suspicion of IBD
is seropositive for both ASCA and anti-MZGP2, this patient is unlikely
to have UC (PPV for CrD: 100%). Also, 12 out of 87 (14%) CrD ASCA neg-
ative patients had anti-MZGP2 antibodies, which could suggest that 14%
of clinically suspicious individuals (whowere reliant on ASCA positivity
for a ﬁrm diagnosis of CrD), could have gone unnoticed, if anti-MZGP2
antibody testing was not ordered in routine testing. It appears that the
detection of MZGP2 autoantibodies can alert the clinician to the poten-
tial presence of CrD and could lead to additional evaluation and close
monitoring of the patient.Please cite this article as: Pavlidis P, et al, Diagnostic and clinical signiﬁcan
novel ELISA, Clin Chim Acta (2014), http://dx.doi.org/10.1016/j.cca.2014.1E
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OWe have found several associations between patients with IgA orIgG anti-MZGP2 antibody reactivities and clinical parameters, using
our new assays, together with the wealth of detailed clinical data avail-
able on the study cohort patients. Some of these associations have been
previously described and are conﬁrmed with our new assay, while
others are novel [12,17,18]. Using earlier ELISAs, we showed that anti-
MZGP2 antibody reactivity is a characteristic feature of patients with
ileocolonic location, and with early disease onset (A1) [12,18]. These
ﬁndings have also been conﬁrmed by the new ELISA testing. Using the
GA ELISA, anti-MZGP2 antibodies may identify patients with stricturing
disease. Intriguingly, stricturing disease (B2) was more likely (OR: 3.1)
in patients testing positive for the presence of ASCA or anti-MZGP2 by
the new ELISA, further underlining the notion that simultaneous testing
of these autoantibodies may have clinical applicability.
Our study has revealed previously unnoticed associations. For exam-
ple, patients positive for IgG anti-MZGP2 were more likely to have
extensive CrD with ileal involvement, which was also the case for IgA
or IgG ASCA (OR: 2.3, 1.7, 1.9, respectively). As this ELISA uses a new
form of the MZGP2 protein (isoform 4) as well as a new assay conﬁgu-
ration, the clinical associations reported here must be validated exter-
nally. Anti-MZGP2 antibodies have recently been determined by a
commercial IFA using GP2-overexpressing cell lines (EUROIMUNN)
[13], however the performance of this IFA compared to our new ELISAs
is currently unknown. It is also of importance to underline the need for
direct comparison of our ELISA and that developed by Generic Assays.
The MZGP2 ELISA is not USA FDA-cleared and therefore is not yet com-
mercially available. Additional studies using “research use only” assays
are in progress and will clarify the relative performance of the GA and
Inova assay.
5. Conclusions
The novel, human recombinant MZGP2, isoform 4, ELISA, and permit-
ting the accurate detection of MZGP2 PAB-speciﬁc autoantibodies, con-
ﬁrmed their high speciﬁcity for CrD as well as their previously described
associations with disease phenotypes. Signiﬁcantly, our study enrolled
the largest number of CrD andUC patients investigated thus far in a single
centre. Someof theﬁndings published in the past have included fewerpa-
tients and cumulative data merged from cohorts of various centres, and
this may explain inconsistencies amongst publications. Prospective stud-
ieswill provide insight into the diagnostic and clinical value of these auto-
antibodies in routine clinical practice.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2014.12.010.
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